@FierceMedDev: Nanotech transforms blood tumor cells into viable Dx tool. News | Follow @FierceMedDev
@MarkHFierce: Smith & Newphew vs. ConvaTec over a wound dressing patent issue; ConvaTec won. Report | Follow @MarkHFierce
@DamianFierce: Privately held CardiacAssist is targeting the heart pump market after getting FDA OK for a pivotal trial. Story | Follow @DamianFierce
> Riverside Methodist Hospital in Columbus, OH, treated the first patient with Cook Medical's new Zilver PTX drug-eluting peripheral stent, following its U.S. Commercial launch. Release
> Allergan ($AGN) has wrapped up its $350 million acquisition of SkinMedica, bolstering its aesthetics business. Item
> Smith & Nephew ($SNN) is extending its Legion knee-replacement system with narrower components designed to help surgeons more closely tailor implants to a patient's natural anatomy. More
> Parallax Diagnostics has completed its merger with Endeavor Holdings, bringing along its FDA-approved Target System VT1000 benchtop assay unit. News
> The global medical devices outsourcing market should rise from $21.1 billion in 2012 to $40.8 billion in 2018, a new market report concludes, as demand increases for outsourced product design, regulatory consulting, testing and validation. Item
> Mass Device surveyed its readers and found, unsurprisingly, that people in the industry are pessimistic that the medical device tax will get repealed. Story
Biotech News
@FierceBiotech: Oncothyreon routed after Merck KGaA's Stimuvax flops in big PhIII lung cancer trial. Story | Follow @FierceBiotech
@JohnCFierce: Ex-GSK scientists grab $18M, neurosciences portfolio for startup. News | Follow @JohnCFierce
@RyanMFierce: Bristol-Myers' Sigal outshines pharma rivals in R&D chief ranking. (Does Jeremy Levin deserve some credit?) More | Follow @RyanMFierce
> Can Big Pharma sustain a swelling rate of new drug approvals? Article
> Regado backers provide $51M to fuel high-stakes PhIII anticoagulant study. News
> Allon shares collapse as ambitious CNS study ends in disastrous flop. Report
Pharma News
@FiercePharma: Lagging Lundbeck cuts its financial outlook for 2013 + 2014, on European sluggishness, R&D costs. More | Follow @FiercePharma
> Actavis CEO's next act may be a Stada buyout. Article
> Pfizer targets 600 primary-care sales jobs. News
Drug Delivery News
> Helix and Merck terminate topical interferon collaboration. Article
> Langer nanoparticle startup Blend bags $16M funding and new CEO. News
> Unigene's oral bone drug doesn't give women the needle. Story
> Drugs sneak through the skin without patches. Item
Biomarkers News
> Myriad to peruse Sanofi insulin trial samples for biomarker clues. Report
> Merck turns to GE agent to track potential Alzheimer's biomarker. Article
> MIT's nanoparticles make cancer biomarkers more visible. News
> Protein doubles as diagnostic and drug target for blood cancer. Story
> SynapDx snags $6M for autism Dx study. Item